"We wanted to implement an opioid minimization pathway that was easy to follow and successful,” says Aaron Laviana, MD.
Aaron Laviana, MD, MBA, discusses the background and results of the study, “Decreased opioid use & equivalent pain score outcomes after urologic robotic surgery using a simplified opioid minimization protocol: a prospective, non-inferiority study,” which he presented at the 2022 AUA Annual Meeting (abstract MP31-02)
Laviana Assistant is a professor of Surgery and Perioperative Care at the University of Texas at Austin Dell Medical School.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.